This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes (TNDM) owing to robust international pump shipments and product launches.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
by Debanjana Dey
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio
by Zacks Equity Research
Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.
Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure
by Zacks Equity Research
Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).
4 Stocks to Watch as Demand for Surgical Robots Ready to Rise
by Kaustav Ghosh
Watch out for the likes of Asensus Surgical (ASXC), Stryker (SYK), Medtronic (MDT) and Intuitive Surgical (ISRG) as demand for surgical robots is set to rise, owing to the conveniences they offer.
Why Is Medtronic (MDT) Down 4.2% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment
by Zacks Equity Research
Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.
The Zacks Analyst Blog Highlights: Alphabet, UnitedHealth, Medtronic, Starbucks and Caterpillar
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, UnitedHealth, Medtronic, Starbucks and Caterpillar
Top Stock Reports for Alphabet, UnitedHealth & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), UnitedHealth Group Incorporated (UNH), and Medtronic plc (MDT).
Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities
by Zacks Equity Research
Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.
Medtronic's (MDT) Emprint Ablation System Study Data Positive
by Zacks Equity Research
Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.
The Zacks Analyst Blog Highlights: Coca-Cola, Danaher, Medtronic, Goldman Sachs and Ford
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coca-Cola, Danaher, Medtronic, Goldman Sachs and Ford
Top Research Reports for Coca-Cola, Danaher & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Danaher Corporation (DHR), and Medtronic plc (MDT).
Medtronic's (MDT) Micra TPS CED Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.
Here's Why You Should Invest In Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 technology and international expansion of the Control-IQ technology add to the company's solid second-quarter performance.
Company News for Aug 25, 2021
by Zacks Equity Research
Companies in The News Are: BBY, MDT, PANW, BMO.
Medtronic (MDT) Receives FDA Nod for Evolut FX TAVR System
by Zacks Equity Research
Medtronic's (MDT) Evolut FX TAVR system offers hemodynamic and durability benefits of the Evolut platform with new product and procedure enhancements.
Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.
Medtronic (MDT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 6.82% and 1.57%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic
by Zacks Equity Research
Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.
Is a Surprise Coming for Medtronic (MDT) This Earnings Season?
by Zacks Equity Research
Medtronic (MDT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Medtronic (MDT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.